GRAIL Partners with Epic to Integrate Galleri Cancer Test into Health Systems
MENLO PARK, Calif., April 7, 2026 — GRAIL, Inc. has announced a partnership with Epic to make the Galleri multi-cancer early detection test more widely available. This collaboration aims to streamline access for about 450 health systems in the U.S. using Epic’s electronic health record (EHR) platform.
With this integration, healthcare providers will be able to order the Galleri test right at the point of care. This means doctors can easily receive test results and manage patient follow-ups without the hassle of navigating multiple systems. By embedding the Galleri test into their regular workflows, clinicians can reduce administrative tasks and enhance the overall experience for both providers and patients.
“Currently, only five cancers have set screening guidelines in the U.S., yet over 70% of cancer-related deaths come from types that lack standard screening,” said Dr. Josh Ofman, President of GRAIL. “By working with Epic, we aim to remove obstacles for healthcare providers, making it simpler to include the Galleri test in regular health checks. Our goal is to catch cancer early, which can significantly improve treatment outcomes.”
Planning for this integration began in early 2026, focusing on early adopter programs and initial implementations. GRAIL will collaborate closely with Epic, AWS, and interested health systems to ensure a smooth rollout. Broad availability of the Galleri test through this integration is expected by the end of 2026.
Alan Hutchison, a Vice President at Epic, emphasized the importance of this partnership: “Aura, our platform, helps health organizations work together by minimizing administrative challenges. With GRAIL onboard, we can push forward the cause of early detection, ultimately enhancing cancer survival rates.”
Dr. Philip Oravetz, Chief Population Health Officer at Ochsner Health, noted that embedding the Galleri test in their existing EHR will alleviate administrative burdens and promote timely patient identification. “When innovative technologies are effectively integrated into healthcare, we can improve patient care and further our focus on preventive health.”
For health systems seeking more information about the Galleri test, visit their dedicated webpage.
About GRAIL
GRAIL is dedicated to early cancer detection. Using advanced technology and research, the company aims to reduce the global cancer burden by identifying multiple cancer types at earlier stages. Based in Menlo Park, CA, GRAIL utilizes next-generation sequencing and innovative software for its tests.
About Galleri
The Galleri test offers a proactive way to screen for over 50 types of cancer from a simple blood sample. It can significantly improve the chances of finding cancer early, which is crucial for effective treatment. The test is especially recommended for adults at elevated risk, such as those aged 50 and older.
Important Safety Information: The Galleri test is not a replacement for standard cancer screenings and should only be used alongside them. It’s not advised for those who are pregnant or under 21, or currently undergoing cancer treatment.
For further details on GRAIL and Galleri, check their official website.
